AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
SGLT2 Inhibitors and Postoperative Atrial Fibrillation in Type 2 Diabetes Following Coronary Artery Bypass Grafting: A Target Trial Emulation
By Ebubechukwu U, Nriagu VC, Tapia Garcia L et al.
Background: Postoperative atrial fibrillation (POAF) affects 30-40% of patients after coronary artery bypass grafting (CABG), increasing stroke and mortality risks. T2DM patients have a higher incidence of POAF, but few studies have examined whether SGLT2 inhibitors (SGLT2i) reduce POAF in this population. Methods: Using a pre-specified target trial emulation framework applied to multi-source real-world data, we included adults with established T2DM undergoing CABG. Patients who were newly initiated on an SGLT2i (empagliflozin or dapagliflozin) were propensity score-matched to non-SGLT2i users. The primary outcome was a 30-day incidence of POAF. Secondary outcomes were ischemic stroke, all-cause mortality, need for electrical cardioversion, and new initiation of amiodarone. Safety endpoints included acute kidney injury or need for renal replacement therapy (AKI/RRT), urinary tract infection (UTI), severe hypoglycemia, volume depletion, and all-cause hospitalization. Results: After matching, 3,276 patients per group were included in the analysis. Overall SGLT2i exposure was not associated with a statistically significant difference in POAF risk (HR 0.92; 95% CI 0.75-1.14). However, a pre-specified dose-restricted (empagliflozin 10mg or dapagliflozin 10mg) cohort (HR 0.72; 95% CI 0.55-0.94) and younger age (HR 0.54; 95% CI 0.39-0.77) were associated with reduced incidence of POAF. No significant between-group differences were observed for ischemic stroke (HR 0.88; 95% CI 0.54-1.43), all-cause mortality (HR 0.85; 95% CI 0.54-1.34), electrical cardioversion (HR 1.16; 95% CI 0.72-1.87), or new amiodarone initiation (HR 1.07; 95% CI 0.97-1.19). Among the safety endpoints, SGLT2i use was associated with a lower incidence of AKI/RRT (HR 0.65; 95% CI 0.50-0.86). Severe hypoglycemia, urinary tract infection, and volume depletion were similar between groups. All-cause hospitalization was more frequent in the SGLT2i cohort. Conclusion: Among T2DM patients undergoing CABG, overall preoperative SGLT2i use was not associated with a reduced incidence of POAF. However, benefits may be more evident in subgroups such as standard-dose users and younger patients. Larger randomized trials are needed to confirm these findings.